PRME · Insider Trading
Prime Medicine, Inc. Common Stock
Every open-market purchase and sale reported by PRME officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-08 | David P Schenkein | Director | A | +75,000 deriv. | — |
| 2026-06-08 | Thomas Cahill | Director | A | +75,000 deriv. | — |
| 2026-06-08 | Wendy Chung | Director | A | +75,000 deriv. | — |
| 2026-06-08 | Robert Nelsen | Director | A | +75,000 deriv. | — |
| 2026-06-08 | Jeffrey D Marrazzo | Director | A | +75,000 deriv. | — |
| 2026-06-08 | Kaye I Foster-Cheek | Director | A | +75,000 deriv. | — |
| 2026-06-08 | Michael Aaron Kelly | Director | A | +75,000 deriv. | — |
| 2026-04-17 | Svetlana Ni Makhni | Chief Financial Officer | A | +800,000 deriv. | — |
| 2026-02-27 | Allan Reine | Chief Executive Officer | A | +1,300,000 deriv. | — |
| 2026-02-24 | Ann L. Lee | Chief Technical Officer | A | +375,000 deriv. | — |
| 2026-02-24 | Carman Alenson | See Remarks | A | +140,000 deriv. | — |
| 2025-08-05 | Robert Nelsen | Director | MIXED | — | — |
| 2025-08-05 | Michael Aaron Kelly | Director | MIXED | — | — |
| 2025-08-05 | David P Schenkein | Director | MIXED | — | — |
| 2025-08-05 | Allan Reine | Chief Executive Officer | MIXED | — | — |
| 2025-08-05 | Carman Alenson | See Remarks | MIXED | — | — |
| 2025-08-05 | Wendy Chung | Director | MIXED | — | — |
| 2025-08-05 | Kaye I Foster-Cheek | Director | MIXED | — | — |
| 2025-08-05 | Thomas Cahill | Director | MIXED | — | — |
| 2025-08-05 | Ann L. Lee | Chief Technical Officer | MIXED | — | — |
| 2025-08-05 | Jeffrey D Marrazzo | Director | MIXED | — | — |
| 2025-08-05 | GV 2021, L.P. | 10%+ Owner | Buy | +1,500,000 | +$4.95M |
| 2025-08-01 | ARCH Venture Partners X, LLC | 10%+ Owner | Buy | +3,030,300 | +$10.00M |
| 2025-08-01 | Robert Nelsen | Director | Buy | +3,030,300 | +$10.00M |
| 2025-08-01 | ARCH Venture Fund XII, L.P. | 10%+ Owner | Buy | +3,030,300 | +$10.00M |
| 2025-07-01 | David R. Liu | 10%+ Owner | Buy | +21,000 | +$52.83K |
| 2025-06-23 | David R. Liu | 10%+ Owner | Buy | +21,000 | +$45.40K |
| 2025-06-16 | David R. Liu | 10%+ Owner | Buy | +21,000 | +$31.20K |
| 2025-06-12 | David R. Liu | 10%+ Owner | Buy | +21,000 | +$33.59K |
| 2025-06-05 | Thomas Cahill | Director | A | +55,000 deriv. | — |
| 2025-06-05 | Kaye I Foster-Cheek | Director | A | +55,000 deriv. | — |
| 2025-06-05 | Robert Nelsen | Director | A | +55,000 deriv. | — |
| 2025-06-05 | Michael Aaron Kelly | Director | A | +55,000 deriv. | — |
| 2025-06-05 | David P Schenkein | Director | A | +55,000 deriv. | — |
| 2025-06-05 | Wendy Chung | Director | A | +55,000 deriv. | — |
| 2025-06-05 | Jeffrey D Marrazzo | Director | A | +55,000 deriv. | — |
| 2025-05-22 | Richard Brudnick | Chief Business Officer | Buy | +20,000 | +$23.79K |
| 2025-05-22 | Allan Reine | Chief Executive Officer | Buy | +125,000 | +$147.15K |
| 2025-05-22 | Ann L. Lee | Chief Technical Officer | Buy | +100,000 | +$113.00K |
| 2025-05-19 | Jeffrey D Marrazzo | Director | A | +800,000 deriv. | — |
| 2025-05-19 | Allan Reine | Chief Executive Officer | A | +2,000,000 deriv. | — |
| 2025-05-12 | Keith Michael Gottesdiener | See Remarks | A | +100,000 deriv. | — |
| 2025-05-12 | Allan Reine | Chief Financial Officer | A | +75,000 deriv. | — |
| 2025-05-12 | Ann L. Lee | Chief Technical Officer | A | +80,416 deriv. | — |
| 2025-03-04 | Keith Michael Gottesdiener | See Remarks | A | +500,000 deriv. | — |
| 2025-03-03 | Ann L. Lee | Chief Technical Officer | A | +275,000 deriv. | — |
| 2025-03-03 | Meredith Goldwasser | SVP, Strategy & Corporate Ops. | A | +90,500 deriv. | — |
| 2025-03-03 | Richard Brudnick | Chief Business Officer | A | +225,000 deriv. | — |
| 2025-03-03 | Allan Reine | Chief Financial Officer | A | +275,000 deriv. | — |
| 2025-03-03 | Jeremy Duffield | Chief Scientific Officer | A | +275,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David R. Liu | 10%+ Owner | 20,240,945 | $87.04M |
| Robert Nelsen | Director | 6,128,297 | $26.35M |
| ARCH Venture Partners X, LLC | 10%+ Owner | 6,128,297 | $26.35M |
| ARCH Venture Fund XII, L.P. | 10%+ Owner | 6,128,297 | $26.35M |
| Thomas Cahill | Director | 4,905,679 | $21.09M |
| GV 2021, L.P. | 10%+ Owner | 3,262,440 | $14.03M |
| Keith Michael Gottesdiener | See Remarks | 2,361,078 | $10.15M |
| Allan Reine | Chief Executive Officer | 125,000 | $537.50K |
| Ann L. Lee | Chief Technical Officer | 100,000 | $430.00K |
| Richard Brudnick | Chief Business Officer | 20,000 | $86.00K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PRME quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.